Edoardo Isnaldi
YOU?
Author Swipe
View article: The role of body mass index at diagnosis in patients with inflammatory breast cancer
The role of body mass index at diagnosis in patients with inflammatory breast cancer Open
View article: Corrigendum to “Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies” [Laboratory Investigation 105(2025) 104202]
Corrigendum to “Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies” [Laboratory Investigation 105(2025) 104202] Open
View article: Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies
Histopathological Insights into Metastatic Breast Cancer Gained From Rapid Autopsies Open
The biology of metastatic breast cancer is poorly understood, and its understanding is hampered by limited access to metastatic tissue. Post-mortem tissue donation programs may represent a step forward to circumvent this problem, allowing …
View article: Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial
Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial Open
View article: Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program Open
Research on metastatic cancer has been hampered by limited sample availability. Here we present the breast cancer post-mortem tissue donation program UPTIDER and show how it enabled sampling of a median of 31 (range: 5-90) metastases and 5…
View article: Metastases of primary mixed no-special type and lobular breast cancer display an exclusive lobular histology
Metastases of primary mixed no-special type and lobular breast cancer display an exclusive lobular histology Open
View article: Supplementary Figure 4 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 4 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 4 shows an overview of tumor emboli assessment.
View article: Supplementary Figure 14 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 14 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 14 shows analyses of the association of sTIL with DRFS.
View article: Supplementary Figure 10 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 10 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 10 shows analyses of the association of pCR with DRFS.
View article: FIGURE 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
FIGURE 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Association of pCR with clinicopathologic features and treatment in all patients. A–C, Forest plots showing the association of pCR with standard clinicopathologic and treatment variables (A), with sTILs (continuous %; B), and with s…
View article: Supplementary Table 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Table 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Table 1 shows clinicopathological characteristics of the entire cohort and the sub-cohort with central pathology performed.
View article: Supplementary Figure 13 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 13 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 13 shows analyses of the association of sTIL with DFS and OS.
View article: Supplementary Figure 7 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 7 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 7 shows subgroup analyses of the association of pCR with clinicopathological and treatment variables.
View article: Supplementary Figure 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 3 shows concordance of sTIL scoring between tumor and skin biopsies.
View article: FIGURE 5 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
FIGURE 5 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Association of pCR with OS. A, Kaplan–Meier curves of OS according to pCR. B, Forest plots showing the association of pCR and standard clinicopathologic and treatment variables with OS quantified by Cox regression.
View article: Supplementary Figure 4 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 4 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 4 shows an overview of tumor emboli assessment.
View article: Supplementary Table 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Table 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Table 3 shows pCR rates and sTIL according to histology.
View article: Supplementary Figure 6 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 6 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 6 shows subgroup analyses of the association of sTIL with clinicopathological variables.
View article: Supplementary Figure 8 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 8 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 8 shows descriptive data of pCR rates according to several pathological features.
View article: FIGURE 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
FIGURE 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
sTIL scoring and its association with clinicopathological features in all patients. A, Distribution of sTIL (continuous) in the entire cohort and in subtypes. B, Distribution of sTIL (category) in the entire cohort and in sub…
View article: Supplementary Figure 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 2 shows an overview of data flow in the study.
View article: Supplementary Figure 12 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 12 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 12 shows analyses of the association of RCB with DRFS.
View article: Data from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Data from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Inflammatory breast cancer (IBC) is a rare (1%–5%), aggressive form of breast cancer, accounting for approximately 10% of breast cancer mortality. In the localized setting, standard of care is neoadjuvant chemotherapy (NACT) ± anti-HER2 th…
View article: Supplementary Figure 14 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 14 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 14 shows analyses of the association of sTIL with DRFS.
View article: Supplementary Figure 9 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 9 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 9 shows potential non-linear association of RCB score with sTIL.
View article: Supplementary Figure 5 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 5 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 5 shows quantile regression analyses of sTIL with clinicopathological variables.
View article: FIGURE 4 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
FIGURE 4 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Association of pCR with DFS. A, Kaplan–Meier curves of DFS according to pCR. B, Forest plots showing the association of pCR and standard clinicopathologic and treatment variables with DFS quantified by Cox regression.
View article: Supplementary Figure 9 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 9 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 9 shows potential non-linear association of RCB score with sTIL.
View article: Supplementary Figure 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 3 shows concordance of sTIL scoring between tumor and skin biopsies.
View article: Supplementary Figure 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
Supplementary Figure 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy Open
Supplementary Figure 1 shows examples of sTIL scoring in skin on H&E images.